Revenue Grows 37%, But the ₹1,350 Crore Margin Gap Says Wait
OneSource delivered strong topline growth (₹449 Cr, +37% YoY) on semaglutide demand, but operating margins stayed flat at 26.5% against a 40% FY28 target. Management reaffirmed $400M guidance, but execution risk on three pending line ramps and margin recovery timing is substantial.
₹449 Cr
+37.2% YoY; validates semaglutide + new customer wins
26.5% vs. 40%
1,350 bps gap; capex opex upfronted today
~₹123 Cr
+39% YoY; margin leverage deferred to FY28
₹25 Cr
+13,539% YoY; base effect. 5.5% NPM is modest.
The core tension: growth is real, margins are not yet
OneSource's Q1 result is two stories. On revenue, the company delivered: ₹449 Cr, up 37.2% YoY, driven by semaglutide adoption (150K–160K pens/month in India, up from 1,350 basis points behind. Management flagged why: capex-related opex is upfronted today across all three new DDC lines now under construction. Margin recovery is deferred until the lines go live and start absorbing fixed costs. In short: revenue is the floor; margins are a promise.
Our first phase of the US$100 million capex, which we have put in our capex, is now reaching fruition with our second cartridge line being set for commercialization in this quarter… the optimal EBITDA contribution is expected when all lines are live.
Where the numbers came from
Net profit of ₹25 Cr (5.5% NPM) is real but modest. The 13,539% YoY growth is optics—it reflects a tiny Q1 FY26 base, not explosive earnings. Revenue growth of 37% is the honest metric. On EBITDA, management claimed 27.4% margin (implied ₹1,233 Cr from ₹4,490 Cr revenue). The delivered operating profit margin is 26.5%, implying ~₹1,191 Cr EBITDA—a ₹42 Cr (3.5%) gap, likely a depreciation treatment difference and immaterial.
Revenue ₹449 Cr, 37% YoY; EBITDA ₹1,233 Cr, 39% YoY
Revenue verified. EBITDA claimed 27.4% vs. OPM delivered 26.5%; 3.5% variance likely depreciation add-back.
Supported (minor variance immaterial)
>40% of India generic semaglutide pens manufactured at our site
MD specific, customer day-one launches confirmed. Market size <2K to 160K pens/month YoY growth validates scale.
Supported
$400M FY28 revenue achievable with clear order book visibility
Q1 annualized run-rate ~₹1,800 Cr vs. $400M (~₹3,300 Cr target). Requires 83% growth. Order book claimed 'visible' but not quantified.
Mixed (credible direction, execution-heavy)
DDC line 1 at full contribution; optimal EBITDA leverage deferred
Revenue-wise full, EBITDA-wise not due to upfronted capex opex. Transparent disclosure.
Supported (honest on timing)
What changed on this call
Formycon biosimilar partnership named. Previously management mentioned a biologics pipeline; this quarter they announced a concrete win with Formycon (a large global biosimilar player). Still pre-commercial (MSA stage, revenue FY29+), but it moves from potential to named. Soft gelatin CDMO services now core. Under Strides, this was captive IP-led. Now OneSource positions it as CDMO services to European customers. Capacity is 2.4B units; tech transfers underway, but full utilization is 12–15 months away (slower than prior expectations). DDC line roadmap reaffirmed. Lines 2, 3, 4 scheduled Q2 FY27, end-FY27, and FY28 respectively. No upgrades to guidance, but timeline is transparent. The $400M target is reaffirmed, not raised.
Revenue growth 37% YoY on semaglutide demand + new customer wins validates thesis
$400M FY28 target backed by order book + clear line roadmap (lines 2, 3, 4 scheduled Q2–FY28)
Multiple new revenue streams (soft gel CDMO, biologics, injectables) diversify concentration
Management transparent: capex opex upfronted, margin recovery FY28+. Not defensive.
OPM flat at 26.5% vs. 40% FY28 target (1,350 bps gap); expansion timing uncertain
Q1 run-rate ₹1,800 Cr annualized vs. $400M (₹3,300 Cr) target; requires 83% growth
Soft gel CDMO ramp now 12–15 months to full utilization; greenfield adds 2–3 year lead time
Biologics pre-commercial (MSA stage); FY29+ revenue at risk
Customer concentration undisclosed; unnamed major dependencies create concentration risk
PAT ₹25 Cr (5.5% NPM) modest; headline 13,539% YoY growth driven by tiny base
Margin expansion timing (1,350 bps to FY28 target)
HighIf line ramps slip or soft gel adoption lags, margin recovery cascades into FY29+. Q1 flat margin despite 37% revenue growth signals leverage is deferred.
DDC line execution delays (3 lines by FY28)
HighEach line adds ~225 sterile days/year. Any 6-month slip reduces FY28 capacity, impacting the $400M target.
Soft gel tech transfer slowdown
MediumNow 12–15 months to full utilization vs. prior expectations. Greenfield expansion (2–3 year lead) may not meet new customer demand on FY28 timeline.
Biologics commercialization delay (FY29+ assumption)
HighLong-term growth pillar. Currently pre-commercial (MSA stage). Regulatory delays, manufacturing scale-up, or adoption shortfalls push revenue.
Unnamed major customer concentration
MediumLoss of any top customer (Dr. Reddy's implied major, others unnamed) materially impacts $400M target.
Semaglutide demand plateau or price compression
MediumCurrently supply-constrained, but generic competition and market maturity could cool momentum.
How the Street is positioned
The stock opened at ₹1,649 pre-result and popped 2.42% on day 1 (44.5% delivery for the result, indicating institutional uptake). By day 3, the pop had extended to +6.11%, but faded sharply: by day 5, the stock was down 1.78% from the pre-result close. That arc—initial enthusiasm, then fade—suggests the Street is taking a 'show me on execution' stance. The stock trades at ₹1,619.7, down 15.86% from its all-time high of ₹1,925 but up 53.24% from its 52-week low. It sits below both the 20-day and 50-day moving averages (₹1,660 and ₹1,685) but above the 200-day average (₹1,615). RSI of 43.8 is neutral. On flows: FII ownership declined QoQ (from 19.24% to 17.50%, −174 bps), while DII ownership rose (from 18.81% to 20.61%, +180 bps). Foreign investors are trimming; domestic investors are adding. Bulk block data shows mixed activity around ₹1,530–₹1,556 with no obvious insider selling near the all-time high. The Street's 6-day fade after a promising result is consistent with the execution bear case—concentration risk, margin timing, three moving parts ahead.
1 · Q2 FY27 – Line 2 commissioning confirmed
DDC line 2 scheduled to go live in Q2 (the current quarter, ending September 2026). This is the first concrete test of the line ramp timeline. Revenue impact will be modest (another ~225 sterile days/year), but it proves execution capability and de-risks lines 3 and 4.
2 · Q3–Q4 FY27 sequential margin inflection
Watch OPM progression closely. Q1 is 26.5%. If Q2 shows flat or lower OPM despite line 2 going live, operating leverage is at risk. Margin expansion should start showing by Q3 as capex opex burdens are absorbed. OPM trending toward 28–30% by Q3 confirms the FY28 thesis is de-risking.
3 · Soft gelatin utilization and biologics commercial launches
Soft gelatin CDMO claimed to reach full utilization (2.4B units) in 12–15 months (H1 FY28). Watch quarterly soft gelatin revenue; if still below ₹150 Cr/quarter, utilization is lagging. For biologics, look for first commercial product revenue (not just MSA). If Formycon stays pre-commercial through Q4 FY27, FY29 commercialization is at risk.
OneSource is executing a step-change, not steady-state. Q1 validated semaglutide demand (37% growth), but the company is now pivoting from single-line DDC to multi-line + CDMO + biologics partnerships, all in parallel, all critical to hitting $400M FY28. This is execution risk, not demand risk.
Management is transparent; Q&A was substantive. But the Street's 6-day fade (pop to +6.11%, then −1.78% by day 5) is telling: investors are correctly adopting a 'prove it' stance. Margin expansion of 1,350 bps in 7 quarters is ambitious; any slip cascades.
For a holder, the single number to track is OPM progression. Q1 is 26.5%. If Q2 shows flat or lower OPM despite line 2 going live, the operating leverage thesis is in trouble and FY28 margins are at risk. If Q3 shows OPM trending toward 28–30%, the guidance is de-risking. Hold for now; upgrade only after Q2 EBITDA inflection is confirmed.
OneSource swings to ₹25 Cr consolidated profit as semaglutide launch lifts revenue 37% YoY
revenue +37.2% · margins expanding · beat vs street
₹449.02 Cr
+37.2% YoY
₹25 Cr
5.52%
+5.6pp YoY
₹2.18
OneSource Specialty Pharma (formerly Stelis Biopharma) turned its June quarter around on a consolidated basis, posting PAT of ₹25.0 Cr against a ₹0.19 Cr loss a year ago, on revenue from operations of ₹449.0 Cr, up 37.2% YoY and 4.9% sequentially. The swing is genuinely operational, not accounting-driven: profit before exceptional items and tax flipped to ₹24.6 Cr from a ₹1.5 Cr loss a year earlier, and operating EBITDA margin expanded to 27.5% (from 27.0% YoY and 21.5% in Q4 FY26). Management attributes the print to the commercial launch of semaglutide in Canada and India, new Master Services Agreement wins, and the addition of another global biosimilar customer to its biologics book.
Q1 FY-2027 vs prior quarters
Two items qualify the headline profit. Reported consolidated PBT of ₹20.3 Cr is struck after a ₹4.30 Cr exceptional legal charge tied to the ongoing Prestige/Sputnik Light manufacturing arbitration at the Singapore International Arbitration Centre (Biolexis subsidiary), and reported PAT of ₹25.0 Cr actually exceeds PBT because of a net ₹0.47 Cr deferred-tax credit — so the bottom line flatters the operating result slightly. Standalone tells a stronger story (PAT ₹51.2 Cr, no exceptional item, nil tax), and the >2x gap to consolidated reflects loss-making subsidiaries and the legal charge that only appear at the group level; readers seeing ₹51 Cr elsewhere should note consolidated ₹25 Cr is the primary basis.
The stock went into the print at ₹1,649, up 5.4% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management reaffirms its long-term guidance of achieving US$400 million in organic revenue with 40% EBITDA margins by FY'28. For the near term, the company anticipates continued and strengthening sequential quarterly growth in revenue and EBITDA through FY'27, driven by the commercial ramp-up of Semaglutide in approved
— This quarter: met
Against guidance, the quarter is on-track: on the Q4 concall management promised strengthening sequential revenue and EBITDA growth through FY27 on the semaglutide ramp, and Q1 delivered both (revenue +4.9% QoQ, margin +600 bps QoQ). Consensus had modelled a final loss for FY26 with breakeven only nearing, so a Q1 group profit lands ahead of the Street's timeline. The concurrent developments fit the narrative — a Formycon AG biosimilar manufacturing partnership and a clean USFDA cGMP inspection support the capacity/demand story, while the Ravi Kumar resignation (Preeti Kalra designated SMP) is a governance change rather than a numbers driver. The key watch is whether the second cartridge line, due commercial in Q2, sustains the sequential ramp management is guiding to.
W1
Second cartridge commercial line due in Q2 FY27 — sustaining the +4.9% QoQ revenue ramp management guides to
W2
EBITDA margin trajectory toward the reaffirmed FY28 target of 40% (from 27.5% now)
W3
Prestige/Sputnik SIAC arbitration (USD 136.32m claim) — quarterly legal-charge drag (₹4.30 Cr this quarter) and any provision
Revenue 37% YoY, margins flat; $400M FY28 target credible but execution-heavy
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Reaffirmed $400M + 40% EBITDA FY28 guidance after Q1 hit 37% YoY growth. Small EBITDA margin variance (claimed 27.4% vs delivered 26.5%) unresolved. Multiple capacity and commercialization moving parts ahead.
Optimistic
next 1–2 quarters
Optimistic
multi-year
OneSource delivered 37% YoY revenue growth on semaglutide demand and new customer wins, with $400M FY28 guidance credibly backed by order book across DDC, soft gel, biologics. Near-term margin expansion deferred: Q1 OPM 26.5% vs 40% FY28 target; capex is upfronting opex. Execution risk on 3 more line ramps by FY28 and biologics commercialization (FY29+). Current quarter is the floor; next 7 quarters execute 7.3x revenue ramp on 1350bps margin improvement.
₹449 Cr
Revenue · +37.2% YoY₹25 Cr
Reported PAT · +13539.2% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue ₹4,490M, 37% YoY; EBITDA 1,233M, 39% YoY
METRevenue ₹449Cr (4,490M) +37.2% YoY verified. EBITDA claimed 27.4% vs OPM delivered 26.5%; 3.5% variance likely depreciation add-back, immaterial.
>40% of India generic semaglutide pens manufactured at our site
METMD specific, customer day-one launches confirmed. Market size <2K to 160K pens/month YoY growth validates scale. Not independently verified but consistent with disclosed customer wins.
$400M FY28 revenue achievable with clear order book visibility
MixedQ1 annualized run-rate ~₹1,800Cr (vs $400M ≈ ₹3,300Cr). Requires 83% CAGR. Order book claimed 'yes' but not quantified; analyst acceptance suggests credibility but unverified.
DDC Line 1 at full contribution per sterile days, optimal EBITDA leverage deferred
METRevenue-wise full, EBITDA-wise not due to upfronted capex-related opex across all lines. Transparent disclosure; expected to resolve as lines load.
Earnings quality
What changed since the last call
Soft gelatin CDMO now ramping
NewUnder Strides was captive IP-led. Now CDMO services; European tech transfers underway. Capacity 2.4B units, 12-15 months to full utilization vs prior assumption faster ramp.
Biologics partnerships moving to named contracts
UpgradeFormycon (large biosimilar player) announced this quarter. RFP funnel 4x YoY. Prior calls mentioned pipeline potential; now concrete wins, but revenue FY29+.
DDC line ramp visibility increased
MaintainedLines 2, 3 scheduled Q2 and end-FY27. Line 4 in FY28. Clear timeline communicated, no change to $400M FY28 target.
The Q&A
Q&A substantive; analysts pressed on line utilization, soft gelatin ramp, capex, biologics timeline, capex. Management answered directly on most. Deflected on CSA/MSA split metrics but not evasive. Tone honest, execution-focused, no defensive posturing.
Soft gelatin capacity scaling — Rupesh Tatiya, Longevity Partners
AnsweredUnder Strides captive, now CDMO services. European players have capacity challenges. Tech transfers take time; expect 12-15 months full utilization. Initiating greenfield expansion.
Dr. Reddy's supply disruption — Abdulkader Puranwala, ICICI Securities
AnsweredNo. Diverse customer base. Pulling demand into Q1. Adding capacity starting Q2. All current capacity full.
Order book for $400M — Abdulkader Puranwala, ICICI Securities
AnsweredYes. Multiple pillars: DDC (3-on-3 Canada, 40% India), biologics (4x RFP funnel), soft gel (being filled), injectables (new capabilities).
Line fungibility and batch scaling — Girish Bakhru, OrbiMed
AnsweredLines fully fungible; customers serviced from both. Batch 200L→500L; most geographies approve quickly, market-by-market basis.
FY29-30 growth trajectory — Gautami Agarwal, Individual Investor
AnsweredYes, EBITDA trajectory continues upward. Biologics commercialize FY29+. Soft gel, injectables ramping. Europe/US DDC opens FY29+.
Biologics contracts and timeline — Pranav Chawla, JM AMC
AnsweredFormycon (large biosimilar player) announced. Animal health win prior quarter. Long-term sticky. Commercialization FY29+, currently MSA. Will expand mammalian/microbial capacity.
Capacity utilization by segment — Ritika Agarwal, The Valuequest
AnsweredDDC, injectables at peak. Soft gel in tech transfer (12-15 months to full). Pre-filled syringes available for new customers.
Capex guidance — Ritika Agarwal, The Valuequest
Partial$100M total, 80% committed (mostly DDC). Biologics capex 'significantly lower' than DDC. No FY27/FY28 split given.
Semaglutide demand dynamics — Anish Jobalia, Girik Capital
AnsweredSupply constraint, not demand. India: <2K to 150K-160K pens/month YoY. Still constrained. All customer forecasts robust.
New line ramp risks — Anish Jobalia, Girik Capital
AnsweredClear demand visibility. Line 2 Q2 FY27, line 3 by year-end. No major risks cited.
Oncology soft gel NDA — Maulik Varia, 360 ONE Capital
AnsweredExpected to launch current quarter. Only one other supplier. Demonstrates capability. Small market, no significant near-term contribution.
Line 1 EBITDA optimization — Nitin Agarwal, DAM Capital
AnsweredRevenue yes (full per-day realization). EBITDA no; opex upfronted across all lines. Optimal EBITDA when all lines live.
Geopolitical and tariff risks — Gaurav Shukla, Finvestor
AnsweredFreight delays (Cape routing), container constraints. Impact muted: all ex-works (customers absorb). US tariff: too early, many admin reversals, no long-term harm expected.
FY27 milestones to monitor — Parth Sodha, Trinetra Asset Management
AnsweredCapacity additions (line 2 Q2, line 3 year-end). Sequential revenue/EBITDA improvement. Operating leverage kicking in.
Guidance
FY28 $400M organic revenue
MediumReaffirmed from prior calls. Requires 83% annualized CAGR from ₹1,800Cr Q1 run-rate. Order book claimed visible; execution risk on 3 line ramps, soft gel CDMO ramp, biologics commercialization.
FY28 40% EBITDA margins
MediumReaffirmed. Requires +1350bps from Q1 26.5% OPM. Relies on revenue growth (fixed cost dilution) and operating leverage. Q1 margin flat despite 37% growth due to upfronted capex opex.
$100M capex program; 80% committed
MediumMostly DDC lines. Additional biologics capex 'significantly lower' than DDC. No FY27/FY28 allocation detail provided.
Risks the call surfaced
DDC line execution
MediumLines 2, 3 must come online on schedule (Q2, Q3-Q4 FY27). Line 4 in FY28. Batch size increases (200L→500L) require market-by-market regulatory approvals. Any delay cascades FY28 guidance.
Soft gelatin tech transfer pace
MediumCapacity 2.4B units; currently in tech transfer phase. Timeline 12-15 months to full utilization. European customers still ramping; delays here squeeze capacity for new customer wins.
Biologics commercialization timing
HighBiologics key to long-term growth beyond FY28. Currently all MSA revenues (development stage). Formycon, animal health contracts assume FY29 commercial launch. Any delay (regulatory approvals, manufacturing scale-up, market adoption) pushes revenue.
Customer concentration
MediumNamed customers: Dr. Reddy's (implied major), Apotex (Canada), Formycon (biosimilars). Others unnamed. Loss of any top customer materially impacts guidance. Concentration not quantified.
Semaglutide demand sustainability
MediumCurrent momentum driven by supply scarcity and latent demand boom (India <2K→160K pens/month YoY). If supply normalizes or demand saturates, growth slows. Generic price compression likely as market matures.
Management
Score 7/10. Clear, specific on technical details (sterile days ~225/line, batch size 200L→500L, line fungibility). Candid about capacity constraints previously, now solving. Strategic withholding on CSA/MSA split and customer names, but not evasive. Transparent on opex timing (margin recovery FY28+). Q1 hit revenue target (37.2% actual vs 37% claimed). Small EBITDA variance (claimed 27.4% vs delivered 26.5% OPM, ~3.5%). Track record: reaffirmed $400M FY28 guidance from prior calls. Multiple moving parts still ahead (line ramps, soft gel ramp, biologics); no execution track record yet.
1 · Q2 FY27
DDC line 2 goes live; doubles sterile days to 450/year
2 · Q3-Q4 FY27
DDC line 3 installation complete; reach 675 sterile days available
3 · H2 FY27
Soft gelatin tech transfers completing; CDMO revenue ramp accelerates
Current quarter is the floor; next 7 quarters execute 7.3x revenue ramp on 1350bps margin improvement.